ResMed exec to take reins at Insulet
By HME News Staff
Updated 8:45 AM CDT, Fri May 6, 2022
.jpg)
ACTON, Mass. – Jim Hollingshead, president of ResMed’s Sleep and Respiratory Care business, will succeed Insulet President and CEO Shacey Petrovic, who is stepping down on June 1. Hollingshead has served as an independent member of Insulet’s board of directors since 2019. Petrovic, who will remain on the board and will serve as an advisor to the company through May 2023, said she was stepping down for family reasons. “It has been an honor to serve as Insulet’s CEO and to have been part of this remarkable team for more than seven years,” said Petrovic. “I am extremely proud of what we have accomplished in my time as CEO. We have made significant strides to improve the lives of people with diabetes, while enhancing Insulet’s ability to innovate and operate with excellence.” In January, the company received clearance from the U.S. Food and Drug Administration for its Omnipod 5, the first tubeless, automated insulin delivery system that offers full compatible smartphone control.
Comments